Physician profile
Mohammad Mobayed
NPI 1114134632
$16,983.71
in general payments reported to CMS, 2019-2025
75 companies · $5,916 in 2025
The $5,916 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.56 · 2020: $26.55 · 2021: $324 · 2022: $2,478 · 2023: $3,267 · 2024: $4,913 · 2025: $5,916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,448 · Consulting Fee: $3,080 · Travel and Lodging: $1,304 · Education: $211 · Gift: $53.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,448.00 |
| Consulting Fee | $3,080.00 |
| Travel and Lodging | $1,303.58 |
| Education | $210.94 |
| Gift | $53.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Oncology Corporate, INC. | $3,749.64 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $3,705.53 | 2022-2025 | Imfinzi, Calquence, Tagrisso |
| Janssen Biotech, INC. | $598.24 | 2019-2025 | Rybrevant, Darzalex, Tecvayli |
| Genentech USA, INC. | $522.72 | 2023-2025 | Tecentriq, Venclexta, Alecensa |
| Eisai INC. | $468.56 | 2021-2025 | |
| Daiichi Sankyo INC. | $454.31 | 2023-2025 | Enhertu, Vanflyta, Datroway |
| Novartis Pharmaceuticals Corporation | $405.63 | 2021-2025 | |
| Sobi, INC | $379.88 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $337.74 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Genzyme Corporation | $320.82 | 2022-2025 | |
| Incyte Corporation | $275.27 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Seagen INC. | $251.17 | 2021-2023 | Padcev |
| Pfizer INC. | $230.08 | 2021-2025 | |
| Glaxosmithkline, LLC. | $226.68 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Astellas Pharma US INC | $217.51 | 2022-2025 | Xtandi, Padcev |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $216.77 | 2019-2025 | Tepmetko |
| Merck Sharp & Dohme LLC | $214.58 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Aveo Pharmaceuticals, INC. | $213.37 | 2021-2025 | |
| Karyopharm Therapeutics INC. | $210.58 | 2022-2025 | Xpovio |
| Lilly USA, LLC | $199.60 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.88 | 2024-2025 | Gilotrif |
| Amgen INC. | $166.60 | 2021-2024 | Prolia, Evenity, Xgeva |
| Celgene Corporation | $157.73 | 2021-2025 | Reblozyl |
| Gilead Sciences, INC. | $154.90 | 2022-2025 | Trodelvy |
| Taiho Oncology, INC. | $138.61 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $132.48 | 2024-2025 | Pyrukynd |
| Kite Pharma, INC. | $131.49 | 2023-2025 | Yescarta |
| Adc Therapeutics America, INC. | $127.96 | 2024-2025 | |
| Abbvie INC. | $127.16 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $126.09 | 2022-2025 | Monoferric, Cosela |
| Octapharma USA, INC. | $117.67 | 2024-2025 | Octagam Immune Globulin (Human), Panzyga |
| Beigene USA, INC. | $102.61 | 2023-2024 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $101.27 | 2023-2024 | Iclusig, Fruzaqla |
| Accord Healthcare, INC. | $98.57 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $98.45 | 2022-2023 | Imbruvica, Epkinly |
| Rigel Pharmaceuticals, INC. | $95.67 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Ipsen Biopharmaceuticals, INC | $94.97 | 2023-2024 | Onivyde, Somatuline Depot |
| Array Biopharma INC | $94.64 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Stemline Therapeutics INC. | $83.18 | 2023-2025 | Orserdu, Elzonris |
| Pharmaessentia USA Corporation | $81.07 | 2024-2025 | Besremi |
| Servier Pharmaceuticals LLC | $78.89 | 2025 | |
| Amneal Pharmaceuticals LLC | $70.78 | 2024-2025 | Avastin, Alymsys |
| Alexion Pharmaceuticals, INC. | $63.50 | 2024-2025 | Ultomiris |
| Iovance Biotherapeutics, INC. | $62.10 | 2025 | Amtagvi |
| Azurity Pharmaceuticals, INC. | $61.78 | 2025 | Vivimusta, Danziten |
| Spectrum Pharmaceuticals INC. | $61.47 | 2023-2025 | Rolvedon |
| Springworks Therapeutics, INC. | $59.44 | 2024 | Ogsiveo |
| Puma Biotechnology, INC. | $58.99 | 2024-2025 | |
| Coherus Oncology, INC. | $56.09 | 2023-2025 | Loqtorzi |
| Apellis Pharmaceuticals, INC. | $53.90 | 2024-2025 | Empaveli |
| Beone Medicines USA, INC. | $52.86 | 2025 | Brukinsa |
| Recordati_rare_diseases_inc. | $52.04 | 2023-2024 | Sylvant, Panhematin |
| Legend Biotech USA INC. | $51.93 | 2025 | Carvykti |
| Kyowa Kirin, INC. | $48.25 | 2024-2025 | Poteligeo |
| Geron Corporation | $44.06 | 2025 | Rytelo |
| Exelixis INC. | $43.22 | 2024-2025 | Cabometyx |
| Cardinal Health 108 LLC | $36.04 | 2024 | |
| Alnylam Pharmaceuticals INC. | $35.49 | 2023-2024 | Givlaari |
| Syndax Pharmaceuticals, INC. | $35.06 | 2025 | |
| Eitan Medical North America, INC. | $33.62 | 2024 | |
| Morphosys, US INC. | $31.76 | 2022-2023 | Monjuvi |
| Tempus Ai, INC | $29.73 | 2024 | |
| Immunocore Limited | $29.36 | 2023 | Kimmtrak |
| Regeneron Healthcare Solutions, INC. | $27.60 | 2024 | Libtayo |
| Genmab U.S., INC. | $25.20 | 2024 | Epkinly |
| Jazz Pharmaceuticals INC. | $23.24 | 2021 | |
| Acrotech Biopharma INC. | $22.38 | 2023 | Beleodaq |
| Organon LLC | $20.50 | 2025 | |
| Deciphera Pharmaceuticals INC. | $19.85 | 2024 | Qinlock |
| Fresenius Kabi USA, LLC | $19.23 | 2024 | Stimufend |
| Ethicon INC. | $18.63 | 2023 | Monarch Platform |
| Integra Lifesciences Corporation | $15.28 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.35 | 2024 | |
| Secura Bio, INC. | $13.14 | 2023 | Copiktra |
| Nestle Healthcare Nutrition INC. | $11.27 | 2020 |
Drugs and devices associated with these payments
Imfinzi $457Lenvima $347Doptelet $327Enhertu $309Sarclisa $207Calquence $203Rybrevant $191Venclexta $190Fotivda $188Opdivo $185Xpovio $181Tecentriq $169Darzalex $159Brukinsa $155Jakafi $155Keytruda $154Padcev $153Inqovi $139Lonsurf $139Carvykti $134Yescarta $131Reblozyl $129Imbruvica $125Alecensa $122Tukysa $122Verzenio $120Ojjaara $120Lynparza $119Trodelvy $119Tecvayli $118Pyrukynd $109Polivy $98.39Zynlonta $97.23Rezlidhia $95.67Tavalisse $95.67Somatuline Depot $94.97Onivyde $94.97Braftovi $94.64Xtandi $94.31Octagam Immune Globulin (Human) $89.21Phesgo $81.67Besremi $81.07Gavreto $79.86Mektovi $79.63Vanflyta $74.97Camcevi $73.49Kisqali $70.51Talvey $69.90Monoferric $69.14Scemblix $68.50Iclusig $66.70Tagrisso $66.06Tecentriq Hybreza $63.80Ultomiris $63.50Rozlytrek $62.81Orserdu $62.60Amtagvi $62.10Rolvedon $61.47Lunsumio $60.32Ogsiveo $59.44Krazati $58.92Datroway $57.16Itovebi $55.04Empaveli $53.90Zejula $52.48Jemperli $52.48Erleada $52.23Balversa $52.23Injectafer $50.87Avastin $50.26Poteligeo $48.25Ibrance $47.21Epkinly $46.12Rytelo $44.06Evenity $43.31Prolia $43.31Cabometyx $43.22Monjuvi $42.59Tivdak $42.18Tepmetko $41.13Vivimusta $37.81Jaypirca $36.45Givlaari $35.49Welireg $34.80Fruzaqla $34.57Vectibix $34.07Nplate $34.07Xgeva $34.07Udenyca $33.12Columvi $30.37Pemazyre $29.72Kimmtrak $29.36Panzyga $28.46Sylvant $27.97Libtayo $27.60Gilotrif $26.95Wayrilz $26.64Kadcyla $26.63Hercessi $25.08Panhematin $24.07
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Mobayed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.